Welcome to our dedicated page for Eton Pharmaceuticals SEC filings (Ticker: ETON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Eton Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Eton Pharmaceuticals's regulatory disclosures and financial reporting.
Eton Pharmaceuticals is a Delaware-based rare disease drug company with a market value of about $360.6 million held by non‑affiliates as of June 30, 2025 and 27,284,491 common shares outstanding as of March 17, 2026. It commercializes eight U.S. rare disease products, including INCRELEX, ALKINDI SPRINKLE, KHINDIVI, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone.
The pipeline includes five late-stage candidates: ET‑600 for diabetes insipidus with a PDUFA goal date of February 25, 2026, Amglidia for neonatal diabetes, ET‑700 for Wilson disease, ET‑800 for adrenal insufficiency and a ZENEO hydrocortisone autoinjector for adrenal crisis. Eton relies on third‑party manufacturers, the FDA’s 505(b)(2) and 505(j) pathways, and maintains patents on key assets extending into the 2030s and 2040s.
The company highlights exposure to U.S. pricing reforms such as the Inflation Reduction Act, government rebate and discount programs, PBM and formulary pressure, global price controls, cybersecurity and AI data risks, counterfeit products, product liability, and strong competition in rare endocrine and metabolic markets.
Eton Pharmaceuticals reported strong fourth quarter and full-year 2025 results, with total net revenues of $79.9 million, up from $39.0 million in 2024. Growth was driven by rare disease products including INCRELEX, ALKINDI SPRINKLE, GALZIN, and KHINDIVI.
Fourth quarter 2025 net revenues were $21.3 million, an 83% increase over the prior-year period, and gross profit rose to $13.1 million. Adjusted EBITDA for 2025 improved to $15.8 million from $2.9 million, while GAAP net loss was $4.6 million. The company posted fourth quarter GAAP net income of $1.5 million.
Eton highlighted the launch of DESMODA, acquisition of orphan drug HEMANGEOL, and advancing clinical programs for INCRELEX label expansion, KHINDIVI reformulation, ET-700, and AMGLIDIA. For 2026, it expects revenue to exceed $110 million with an Adjusted EBITDA margin of at least 30%, indicating confidence in continued growth and improving profitability.
Eton Pharmaceuticals has acquired U.S. commercialization rights to HEMANGEOL, an Orphan Drug for infantile hemangioma, through a licensing deal with Pierre Fabre Medicament Sas. Eton will pay $14.0 million upfront, plus an 8% royalty on net U.S. sales for the product’s patent life.
The company will buy about $1.5 million of inventory at closing and an estimated $0.7 million in May 2026, funded from existing cash. Pierre Fabre will distribute HEMANGEOL in the U.S. until April 30, 2026, after which Eton will take over. Management expects the transaction to be accretive to 2026 earnings.
According to IQVIA data, HEMANGEOL generated $11.7 million in U.S. sales in 2025. It is currently the only treatment indicated for proliferating infantile hemangiomas requiring systemic therapy, with an estimated 5,000–10,000 infants treated annually in the United States.
Eton Pharmaceuticals reported that the U.S. FDA has approved its New Drug Application for DESMODA (desmopressin acetate) Oral Solution to manage central diabetes insipidus, or arginine vasopressin deficiency, in patients of all ages. DESMODA is described as the first and only FDA‑approved oral liquid formulation of desmopressin, designed for precise, individualized dosing in a condition where careful titration is critical to maintaining water balance.
The product is supplied as a ready‑to‑use 0.05 mg/mL solution that avoids tablet splitting, crushing, refrigeration, mixing, or shaking. Eton estimates more than 13,000 U.S. patients have central diabetes insipidus, including 3,000–4,000 pediatric patients, and expects DESMODA peak annual sales of $30–50 million. DESMODA will be promoted by Eton’s existing pediatric endocrinology rare disease team and is expected to be available on March 9 exclusively through specialty pharmacy Anovo, which will run the Eton Cares support program with services such as prescription fulfillment, insurance investigation, education, and financial assistance.
Eton Pharmaceuticals director Norbert G. Riedel reported exercising stock options and acquiring additional common shares. On 02/03/2026, he exercised an employee stock option for 30,000 shares of common stock at $4.42 per share.
Following this transaction, he directly held 35,000 shares of Eton Pharmaceuticals common stock. He also had indirect beneficial ownership of 157,145 shares held in the “Norbert G. Riedel 2002 Trust, Loan Thi Tran 2002 Trust” family trust, where he serves as a trustee.
Eton Pharmaceuticals reported that it has licensed U.S. marketing rights to an ultra-rare disease product candidate. The product, once approved, is expected to be the first and only generic alternative to an existing treatment for an ultra-rare condition affecting fewer than 100 patients in the United States.
The licensing arrangement was disclosed through a press release dated February 2, 2026, which is attached as an exhibit to the report.
Eton Pharmaceuticals director Norbert G. Riedel reported new equity compensation grants. On January 12, 2026, he was granted options to purchase 12,196 shares of common stock at an exercise price of $15.47 per share. These options vest quarterly over 12 months from the grant date and are scheduled to be fully vested and exercisable by January 12, 2027.
On the same date, he also received 7,757 restricted stock units (RSUs), each representing a contingent right to receive one share of Eton common stock. The RSUs vest in four equal annual installments beginning January 12, 2027, contingent on his continued service with the company on each vesting date. Following these grants, he beneficially owns 294,253 derivative securities directly.
Eton Pharmaceuticals director Adams Jennifer McKie reported new equity awards. On January 12, 2026, she received an employee stock option grant for 12,196 shares with an exercise price of $15.47 per share. These options vest quarterly over 12 months from the grant date and are expected to be fully vested and exercisable by January 12, 2027.
She also received 7,757 restricted stock units (RSUs), each representing a contingent right to receive one share of Eton common stock. The RSUs vest in one annual installment beginning January 12, 2027, contingent on her continued service with the company on the vesting date(s). Following these grants, she beneficially owns 170,329 derivative securities related to stock options and 178,086 derivative securities related to RSUs, all held directly.
Eton Pharmaceuticals director Charles J. Casamento reported new equity awards. On January 12, 2026, he received an employee stock option covering 12,196 shares of Eton common stock with an exercise price of $15.47 per share. According to the filing, these option shares vest quarterly over 12 months from the grant date and become fully vested and exercisable on January 12, 2027.
On the same date, he was also granted 7,757 restricted stock units. Each RSU represents a contingent right to receive one share of Eton common stock. These RSUs vest in a single annual installment beginning January 12, 2027, conditioned on his continued employment with the company on the vesting date. Following these grants, he beneficially owned 295,171 derivative securities related to options and 302,928 derivative securities related to restricted stock units.
Eton Pharmaceuticals director Paul V. Maier reported new equity awards. On January 12, 2026, he received an employee stock option for 12,196 shares of common stock at a $15.47 exercise price. These options vest quarterly over 12 months from the grant date and are fully exercisable on January 12, 2027.
He also received 7,757 restricted stock units, each representing a contingent right to one share of Eton common stock. These RSUs vest in one annual installment beginning January 12, 2027, contingent on his continued employment with the company. After these derivative awards, the filing shows 286,496 derivative securities following the option grant and 294,253 following the RSU grant, all held directly.